Stelios K. Mylonas

Stelios K. Mylonas

Auto-generated profile, based on publicly available information

Stelios K. Mylonas

Centre for Research and Technology Hellas (CERTH)

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2021 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
SMStelios K Mylonas
Stelios K Mylonas
AAApostolos Axenopoulos
Apostolos Axenopoulos
PDPetros Daras
Petros Daras
The knowledge of potentially druggable binding sites on proteins is an important preliminary step toward the discovery of novel drugs. The computational prediction of such areas can be boosted by following the recent major advances in the deep learning field and by exploiting the increasing availability of proper data. In this article, a novel computational method for the prediction of potential binding sites is proposed, called DeepSurf. DeepSurf combines a surface-based representation, where a number of 3D voxelized grids are placed on the protein’s surface, with state-of-the-art deep learning architectures. After being trained on the large database of scPDB, DeepSurf demonstrates superior results on three diverse testing datasets, by surpassing all its main deep learning-based competitors, while attaining competitive performance to a set of traditional non-data-driven approaches. The source code of the method along with trained models are freely available at https://github.com/stemylonas/DeepSurf.git. Supplementary data are available at Bioinformatics online.

1 December 2013 in Knowledge-Based Systems
Verified
Journal Article
Closed access
SMStelios K. Mylonas
Stelios K. Mylonas
Dimitris StavrakoudisDimitris Stavrakoudis
Dimitris Stavrakoudis
JTJohn Theocharis
John Theocharis

13 November 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
IGIoannis Gkekas
Ioannis Gkekas
SKSotirios Katsamakas
Sotirios Katsamakas
SMStelios Mylonas
Stelios Mylonas
TFTheano Fotopoulou
Theano Fotopoulou
George MagoulasGeorge Magoulas
George Magoulas
SPSpyros Petrakis
Spyros Petrakis
Coronavirus disease 2019 (COVID-19) is caused by a new, highly pathogenic severe-acute-respiratory syndrome coronavirus 2 (SARS-CoV-2) that infects human cells through its transmembrane spike (S) glycoprotein. The receptor-binding domain (RBD) of the S protein interacts with the angiotensin-converting enzyme II (ACE2) receptor of the host cells. Therefore, pharmacological targeting of this interaction might prevent infection or spread of the virus. Here, we performed a virtual screening to identify small molecules that block S-ACE2 interaction. Large compound libraries were filtered for drug-like properties, promiscuity and protein-protein interaction-targeting ability based on their ADME-Tox descriptors and also to exclude pan-assay interfering compounds. A properly designed AI-based virtual screening pipeline was applied to the remaining compounds, comprising approximately 10% of the starting data sets, searching for molecules that could bind to the RBD of the S protein. All molecules were sorted according to their screening score, grouped based on their structure and postfiltered for possible interaction patterns with the ACE2 receptor, yielding 31 hits. These hit molecules were further tested for their inhibitory effect on Spike RBD/ACE2 (19-615) interaction. Six compounds inhibited the S-ACE2 interaction in a dose-dependent manner while two of them also prevented infection of human cells from a pseudotyped virus whose entry is mediated by the S protein of SARS-CoV-2. Of the two compounds, the benzimidazole derivative CKP-22 protected Vero E6 cells from infection with SARS-CoV-2, as well. Subsequent, hit-to-lead optimization of CKP-22 was effected through the synthesis of 29 new derivatives of which compound CKP-25 suppressed the Spike RBD/ACE2 (19-615) interaction, reduced the cytopathic effect of SARS-CoV-2 in Vero E6 cells (IC50 = 3.5 μM) and reduced the viral load in cell culture supernatants. Early in vitro ADME-Tox studies showed that CKP-25 does not possess biodegradation or liver metabolism issues, while isozyme-specific CYP450 experiments revealed that CKP-25 was a weak inhibitor of the CYP450 system. Moreover, CKP-25 does not elicit mutagenic effect on Escherichia coli WP2 uvrA strain. Thus, CKP-25 is considered a lead compound against COVID-19 infection.

16 February 2021 in arXiv
Verified
Preprint
Open access
PDF file
SMStelios K. Mylonas
Stelios K. Mylonas
AAApostolos Axenopoulos
Apostolos Axenopoulos
PDPetros Daras
Petros Daras
The knowledge of potentially druggable binding sites on proteins is an important preliminary step towards the discovery of novel drugs. The computational prediction of such areas can be boosted by following the recent major advances in the deep learning field and by exploiting the increasing availability of proper data. In this paper, a novel computational method for the prediction of potential binding sites is proposed, called DeepSurf. DeepSurf combines a surface-based representation, where a number of 3D voxelized grids are placed on the protein's surface, with state-of-the-art deep learning architectures. After being trained on the large database of scPDB, DeepSurf demonstrates superior results on three diverse testing datasets, by surpassing all its main deep learning-based competitors, while attaining competitive performance to a set of traditional non-data-driven approaches.


30 April 2026
Verified
Book Chapter
Closed access
PDF file
CKChristos Koutlis
Christos Koutlis
APAlessandro Pianese
Alessandro Pianese
Davide CozzolinoDavide Cozzolino
Davide Cozzolino
MSManos Schinas
Manos Schinas
SMStelios Mylonas
Stelios Mylonas
Symeon PapadopoulosSymeon Papadopoulos
Symeon Papadopoulos